Based on the HIV-1 tropism, drugs have been developed against the CCR5 co-receptor Maraviroc (MVC) is a CCR5-blocking drug that was approved for the treatment of HIV-1 infection [26], and Vicriviroc, which binds to CCR5 of human cells and inhibits the entry of HIV-1 into CD4 cells was never approved by the US FDA [27]. The gene discussed is CCR5; the disease is HIV-1 infection.